{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-002986","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.687172+00:00","generated_at":"2026-06-04T22:51:16.132249+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MaxCyte Q4 revenue $15.7M (+26% YoY) but core down 32%; net loss $5.3M; reiterates 2024 guidance","bullets":["Q4 total revenue $15.7M (+26% YoY); core business revenue $7.2M (-32%); SPL program-related $8.5M (+359%).","Full year 2023 revenue $41.3M (-7% YoY); net loss $37.9M vs. $23.6M loss in 2022.","Cash, equivalents and investments $211.2M at Dec 31, 2023; expects ~$175M at end of 2024.","23 active SPLs at year-end, 3 more signed in Jan 2024 (now 26); 16 licensed clinical programs.","2024 guidance: core revenue flat to +5% YoY; SPL program-related ~$3M; excludes CASGEVY milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-002986","json":"https://secwatch.observer/filing/0001558370-24-002986.json","markdown":"https://secwatch.observer/filing/0001558370-24-002986.md","text":"https://secwatch.observer/filing/0001558370-24-002986.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000155837024002986/0001558370-24-002986-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000155837024002986/mxct-20240312x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:51:16.132249+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e2a15715ea7f20c2a9258485bb8af294f62480c3","claim":"MAXCYTE, INC. reported quarter and year ended December 31, 2023 results: revenue Total revenue of $15.7 million in the fourth quarter of 2023, net income Fourth quarter 2023 net loss was $5.3 million. Guidance reaffirmed.","evidence_excerpt":"MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1287098/000155837024002986/0001558370-24-002986-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter and year ended December 31, 2023"},{"label":"Revenue","value":"Total revenue of $15.7 million in the fourth quarter of 2023"},{"label":"Net income","value":"Fourth quarter 2023 net loss was $5.3 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}